/AADI

AADI Stock - Aadi Bioscience, Inc.

Q: What is the analyst price target for AADI?

Analyst price target information is not currently available for AADI.

Q: What is AADI's market cap?

Market capitalization information is not currently available for AADI.

Healthcare|Biotechnology|NASDAQ

$2.05-2.38%

$0.05 (-2.38%) • Mar 18

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-20.5%upside

Target: $1.63

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for AADI

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.34

52W High$3.81

52W Low$1.21

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$25.98M	$24.35M	$15.22M	$1.12M	$14.00M
Gross Profit	$22.96M	$21.55M	$13.88M	$-18,550,000	$13.82M
Gross Margin	88.4%	88.5%	91.2%	-1656.3%	98.7%
Operating Income	$-67,458,000	$-71,933,000	$-58,957,000	$-111,217,000	$-2,549,000
Net Income	$-63,691,000	$-65,765,000	$-60,513,000	$-110,090,000	$-3,478,000
Net Margin	-245.1%	-270.0%	-397.7%	-9829.5%	-24.8%
EPS	$-2.36	$-2.44	$-2.69	$-12.41	$-26.34

Company Overview

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

Hold / Neutral

100%

Sell / Underperform

Analyst Consensus🔴 Bearish

0 Bullish4 Neutral/Bearish

Price Targets

Average Target

↓ 20.7% Downside

Now

Low

Average

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
August 27th 2024	Piper Sandler	Downgrade	Neutral	$1.75← $5
August 21st 2024	Jefferies	Downgrade	Hold	$1.5← $11
August 21st 2024	TD Cowen	Downgrade	Hold	-
December 15th 2023	H.C. Wainwright	Downgrade	Neutral	-

Earnings History & Surprises

AADI

Beat Rate

59%

Last 17 quarters

Avg Surprise

-3.2%

EPS vs Estimate

Beats / Misses

10/5

2 met exactly

Latest EPS

$-0.26

Q4 2025

EPS Surprise History

Q1 24

+10.4%

$-0.60vs$-0.67

Q2 24

-3.0%

$-0.68vs$-0.66

Q3 24

+23.9%

$-0.54vs$-0.71

Q4 24

0.0%

$-0.46vs$-0.46

Q1 25

-123.3%

$-0.67vs$-0.30

Q2 25

No data

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 4, 2025	—	$-0.26	—	—
Q3 2025	Aug 5, 2025	—	$-0.76	—	—
Q2 2025	May 6, 2025	—	$1.83	—	—
Q1 2025	Mar 18, 2025	$-0.30	$-0.67	-123.3%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.46	$-0.46	0.0%	= MET
Q3 2024	Aug 7, 2024	$-0.71	$-0.54	+23.9%	✓ BEAT
Q2 2024	May 8, 2024	$-0.66	$-0.68	-3.0%	✗ MISS
Q1 2024	Mar 13, 2024	$-0.67	$-0.60	+10.4%	✓ BEAT
Q4 2023	Nov 8, 2023	$-0.73	$-0.60	+17.8%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.64	$-0.67	-4.7%	✗ MISS
Q2 2023	May 10, 2023	$-0.58	$-0.57	+1.7%	✓ BEAT
Q1 2023	Mar 28, 2023	$-0.65	$-0.52	+20.0%	✓ BEAT
Q4 2022	Nov 9, 2022	$-0.75	$-0.68	+9.3%	✓ BEAT
Q3 2022	Aug 10, 2022	$-0.72	$-0.73	-1.4%	✗ MISS
Q2 2022	May 12, 2022	$-0.68	$-0.66	+2.9%	✓ BEAT
Q1 2022	Mar 17, 2022	$-0.98	$-0.77	+21.4%	✓ BEAT
Q4 2021	Nov 10, 2021	$-0.59	$-1.37	-132.2%	✗ MISS
Q3 2021	Aug 11, 2021	$-6.00	$-1.35	+77.5%	✓ BEAT
Q2 2021	May 17, 2021	$-1.35	$-1.35	0.0%	= MET
Q1 2021	Mar 11, 2021	$-2.02	$-1.50	+25.7%	✓ BEAT

Frequently Asked Questions about AADI

What is AADI's current stock price?

Aadi Bioscience, Inc. (AADI) is currently trading at $2.05 per share. The stock has moved -2.38% today.

What is the analyst price target for AADI?

The average analyst price target for AADI is $1.63, based on 1 analyst.

What sector is Aadi Bioscience, Inc. in?

Aadi Bioscience, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is AADI's market cap?

Aadi Bioscience, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.

Does AADI pay dividends?

No, Aadi Bioscience, Inc. does not currently pay a dividend to shareholders.